unknown
Stage
About
Artielle develops novel first-in-class biologic therapies targeting neuroinflammatory diseases and advanced cancers, using a platform that modulates immune cell activity to treat conditions such as multiple sclerosis, substance use disorder, stroke, and advanced melanoma.
Explore Artielle's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.